Vertex Pharmaceuticals (VRTX)
(Delayed Data from NSDQ)
$472.00 USD
+0.56 (0.12%)
Updated Aug 15, 2024 04:00 PM ET
Pre-Market: $471.33 -0.67 (-0.14%) 8:20 AM ET
3-Hold of 5 3
D Value F Growth D Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$472.00 USD
+0.56 (0.12%)
Updated Aug 15, 2024 04:00 PM ET
Pre-Market: $471.33 -0.67 (-0.14%) 8:20 AM ET
3-Hold of 5 3
D Value F Growth D Momentum F VGM
Zacks News
The company’s main area of focus is cystic fibrosis (CF). The company’s lead marketed products are Trikafta (elexacaftor/tezacaftor/ivacaftor and ivacaftor), Symdeko/Symkevi (tezacaftor in combination with ivacaftor), Orkambi (lumacaftor in combination with ivacaftor) and Kalydeco (ivacaftor), which are collectively approved to treat the majority of the people with CF in North America, Europe and Australia. Trikafta, Vertex’s triple combination regimen, was approved by the FDA in October 2019 for the treatment of CF in people aged 12 years and older who have at least one F508del mutation. Kaftrio (brand name of Trikafta in EU) was approved in the European Union in August 2020. It is also being evaluated in younger patients in the United States. With approval of Trikafta, Vertex can address a significantly larger CF patient population — almost 90% of patients with CF — in the future. Meanwhile, Vertex is pursuing genetic therapies to address the remaining 10% of CF patients. While CF remains the main area of focus, Vertex is also developing treatments for sickle cell disease, thalassemia and pain management.
Vertex Pharmaceuticals (VRTX) Registers a Bigger Fall Than the Market: Important Facts to Note
by Zacks Equity Research
Vertex Pharmaceuticals (VRTX) reachead $397.58 at the closing of the latest trading day, reflecting a -1.71% change compared to its last close.
Is iShares Biotechnology ETF (IBB) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for IBB
Vertex (VRTX) Moves Kidney Disease Drug to Phase 3 Development
by Zacks Equity Research
Vertex (VRTX) advances inaxaplin to late-stage development. It will evaluate the drug in lower age groups and will enroll patients aged 10 years and older with APOL1-mediated kidney disease.
Vertex Pharmaceuticals (VRTX) Increases Despite Market Slip: Here's What You Need to Know
by Zacks Equity Research
In the closing of the recent trading day, Vertex Pharmaceuticals (VRTX) stood at $420.48, denoting a +0.59% change from the preceding trading day.
Brokers Suggest Investing in Vertex (VRTX): Read This Before Placing a Bet
by Zacks Equity Research
According to the average brokerage recommendation (ABR), one should invest in Vertex (VRTX). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?
Should You Invest in the iShares Biotechnology ETF (IBB)?
by Zacks Equity Research
Sector ETF report for IBB
bluebird (BLUE) Misses on Q4 Revenues, Provides Portfolio Updates
by Zacks Equity Research
bluebird bio (BLUE) revenues miss the Zacks Consensus Estimate in the fourth quarter. The company progresses with the launch of its three approved gene therapies.
Vertex Pharmaceuticals (VRTX) Rises As Market Takes a Dip: Key Facts
by Zacks Equity Research
In the most recent trading session, Vertex Pharmaceuticals (VRTX) closed at $416.03, indicating a +0.09% shift from the previous trading day.
Vertex (VRTX) Continues to Diversify Beyond CF Franchise
by Zacks Equity Research
While CF remains the main area of focus for Vertex Pharmaceuticals (VRTX), it is seeing success in the development of its non-CF pipeline candidates.
Vertex (VRTX) Kidney Disease Drug to Enter Clinical Development
by Zacks Equity Research
Vertex Pharmaceuticals (VRTX) plans to begin a phase I study on VX-407 in autosomal dominant polycystic kidney disease later this month.
bluebird (BLUE) Gets $175 Million Loan From Hercules, Shares Up
by Zacks Equity Research
bluebird (BLUE) obtains a $175 million five-year, term loan facility from Hercules that stretches its cash runaway by two years. The company's shares rise on the news.
Vertex Pharmaceuticals (VRTX) Beats Stock Market Upswing: What Investors Need to Know
by Zacks Equity Research
In the closing of the recent trading day, Vertex Pharmaceuticals (VRTX) stood at $411.38, denoting a +0.91% change from the preceding trading day.
Should You Invest in the Invesco Biotechnology & Genome ETF (PBE)?
by Zacks Equity Research
Sector ETF report for PBE
Vertex Pharmaceuticals (VRTX) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Vertex Pharmaceuticals (VRTX) closed the most recent trading day at $412.45, moving -0.49% from the previous trading session.
Vertex (VRTX) Down 0.2% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Vertex (VRTX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
GSK vs. VRTX: Which Stock Is the Better Value Option?
by Zacks Equity Research
GSK vs. VRTX: Which Stock Is the Better Value Option?
Is Invesco Biotechnology & Genome ETF (PBE) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for PBE
Editas (EDIT) Q4 Earnings & Revenues Top Estimates, Stock Up
by Zacks Equity Research
Editas (EDIT) reports better-than-expected fourth-quarter 2023 results as both earnings and revenues beat estimates, driven by collaboration revenues received from Vertex. The stock gains 25%.
The Zacks Analyst Blog Highlights JPMorgan Chase, Salesforce, Vertex Pharmaceuticals, Palo Alto Networks and The Williams Companies
by Zacks Equity Research
JPMorgan Chase, Salesforce, Vertex Pharmaceuticals, Palo Alto Networks and The Williams Companies are part of the Zacks top Analyst Blog.
Top Stock Reports for JPMorgan Chase, Salesforce & Vertex Pharmaceuticals
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including JPMorgan Chase & Co. (JPM), Salesforce, Inc. (CRM) and Vertex Pharmaceuticals Incorporated (VRTX).
CRISPR (CRSP) Q4 Earnings Top on Collaboration Revenues, Stock Up
by Zacks Equity Research
CRISPR (CRSP) gains on encouraging fourth-quarter 2023 results, beating both earnings and revenue estimates on the back of collaboration revenues received from Vertex.
Biotech Stock Roundup: BIIB's Q4 Results, CBAY Up on GILD's Acquisition & Other Updates
by Zacks Equity Research
Earnings from Biogen (BIIB) and CymaBay (CBAY) are in focus in the biotech sector.
CRISPR (CRSP) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
On CRISPR's (CRSP) fourth-quarter 2023 earnings call, investors' focus is likely to be on the company's progress with the launch activities of the newly approved gene therapy, Casgevy (exa-cel).
Vertex (VRTX), CRSP's Casgevy Gets EU Nod for Two Blood Disorders
by Zacks Equity Research
Following the approval of Vertex (VRTX) and CRISPR Therapeutics' (CRSP) Casgevy, approximately 8,000 patients, 12 years of age and older, with SCD or TDT in Europe, become potentially eligible for treatment.
Should You Invest in the VanEck Biotech ETF (BBH)?
by Zacks Equity Research
Sector ETF report for BBH